News
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...
A filing with the state details the Columbus job cuts for a biotech cutting more than one-third of its workforce.
On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.
British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback